Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pharmacogenetic applications of the Human Genome project

Nature Medicine volume 7, pages 281–283 (2001)Cite this article

Basic research and clinical studies are underway to identify genetic polymorphisms that underlie drug effects. What obstacles must we overcome before we can use genetic analysis to predict the ability of patients to respond to certain treatments?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Application of human genetic diversity to pharmacogenetics.

References

  1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).

  2. The International SNP Map Working Group. A map of human genome sequence variation containing 1.4 million single nucleotide polymorphisms Nature 409, 928–933 (2001).

  3. Malmstron, K. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, control trial. Ann. Intern. Med. 130, 487–495 (1999).

    Article  Google Scholar 

  4. Drazen, J.M., Silverman, E.R. & Lee, T.H. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. (in the press).

  5. Fullerton, S.A. et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 67, 881–900 (2000).

    Article  CAS  Google Scholar 

  6. Drysdale C.M. et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Nat. Acad. Sci. USA 97, 10483–10488 (2000).

    Article  CAS  Google Scholar 

  7. Small, K., Forbes, S.L., Rahman, F.F., Bridges, K.M. & Liggett, S.B. A four amino acid deletion polymorphism in the third intracellular loop of the human α2c-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275, 23059–23064 (2000).

    Article  CAS  Google Scholar 

  8. Judson, R., Stephens, J.C. & Windemuth, A. The predictive power of haplotypes in clinical response. Pharmacogenomics 1, 2–23 (2000).

    Article  Google Scholar 

  9. Ulbrecht, M. et al.Association of β(2)-adrenoreceptor variants with bronchial hyperresponsiveness. Am. J. Respir. Crit. Care. Med. 161, 469–474 (2000).

    Article  CAS  Google Scholar 

  10. Drazen, J.M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pharmacology University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

    Stephen B. Liggett

Authors
  1. Stephen B. Liggett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liggett, S. Pharmacogenetic applications of the Human Genome project. Nat Med 7, 281–283 (2001). https://doi.org/10.1038/85411

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/85411

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing